Compare Nomura Holdings Inc (NMR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Recursion Pharmaceuticals Inc — how do they compare? Nomura Holdings Inc trades at $9.49 (market cap $28.05B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Nomura Holdings Inc is far larger — about 12.1× Recursion Pharmaceuticals Inc's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NMR | RXRX | |
|---|---|---|
Market Cap | $28.05B | $2.31B |
Volume | 729,574 | 40,478,768 |
Sector | Financials | Health |
52-Week High | $10.86 | $6.79 |
52-Week Low | $6.73 | $2.84 |
Typical Hold Time | 55 Days | 22 Days |
Enterprise Value | $38.55T | $1.83B |
Dividend Yield | 3.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.54, down 2.45% today, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $1.38T in 2024 to $1.66T in 2025 and net income surging to $340.74B. Valuation metrics appear attractive with P/E of 11.29 and P/B of 1.15, while analyst consensus leans toward Hold (66.67%) with some positive momentum coverage from Zacks.
The outlook presents a mixed picture - strong profitability and reasonable valuation support upside potential, but negative operating cash flows and increasing debt-to-asset ratios pose significant risks. Recent technical weakness suggests near-term pressure, though fundamental strength could drive recovery if earnings momentum continues.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
